Best Life Sciences Platforms and Tools Companies in Cambridge, United States
The 69 best Life Sciences Platforms and Tools companies in Cambridge, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tessera Therapeutics.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Tessera Therapeutics Provider of new genome engineering technology for treating multiple diseases | $532M | 50 mo ago | 203 | 2017 | Robert Citorik Co-Founder & Director | Craft CMSPHPYii+10 | — | — |
| 2 | LifeMine Therapeutics Developer of novel drugs from fungi via genome mining and recombinant overexpression | $300M | 51 mo ago | 85 | 2016 | Weiqing Zhou Co-Founder & COO | — | — | — |
| 3 | ReNAgade Developer of RNA-based medicines to treat multiple diseases | $300M | 37 mo ago | 136 | 2021 | — | — | — | — |
| 4 | Remix Therapeutics Developer of RNA processing therapeutics to treat multiple diseases | $211M | 30 mo ago | 56 56 → 50 (-11%) | 2019 | Peter Smith Co-Founder | — | 202 patents Small-molecule modulators of RNA splicing targeting alternative splice site regulation | 4 job openings |
| 5 | KSQ Drug discovery company employing functional genomics technology | $157M | 92 mo ago | 95 95 → 58 (-39%) | 2015 | Tim Wang Co-Founder | WordPressApple iCloud MailMySQL+16 | — | — |
| 6 | Warp Drive Bio Discovery platform to find drugs for undruggable cancers | $125M | 173 mo ago | 50 | 2012 | — | — | — | — |
| 7 | Quanterix Developer of assay kits for ultra-sensitive biomarker detection | $97M | 50 mo ago | 141 | 2007 | — | WordPressSentryApple iCloud Mail+39 | 138 patents Ultra-sensitive digital immunoassays for protein biomarkers in clinical diagnostics | 3 launchs · 2 partnerships |
| 8 | Cydan Online platform providing Togel Hongkong results, data, and live draws | $91M | 104 mo ago | 7 | 2013 | — | — | — | — |
| 9 | Glympse Bio Provider of noninvasive and predictive monitoring of multiple human diseases | $79M | 72 mo ago | 21 | 2015 | — | — | — | — |
| 10 | Ra Pharmaceuticals Developing complement system inhibitors (peptides) for rare diseases. | $77M | 131 mo ago | 92 | 2008 | — | — | 437 patents Small‑molecule modulators of CXCR4/CXCR2, Btk, IL‑6 and complement pathways | — |
| 11 | Helicos BioSciences DNA-sequencing instrument based on imaging individual DNA molecules. | $77M | 192 mo ago | 12 | 2002 | — | — | 241 patents High-throughput nucleic acid sequencing, single‑cell analysis, and synthetic nucleotide technologies | — |
| 12 | ViaCell Provider of services for collecting and preserving umbilical cord blood stem cells | $63M | 295 mo ago | 254 | 1994 | Cynthia Fisher Co-Founder | — | 30 patents Red blood cell preservation and rejuvenation formulations; stem‑cell ischemia treatments. | — |
| 13 | ReadCoor Innovating single-cell, spatial, and in situ biology tools for researchers | $56M | 77 mo ago | 53 | 2016 | — | — | 29 patents Spatial genomics: high‑resolution mapping of DNA/RNA variants in tissue sections | 1 partnership |
| 14 | Gen9 DNA solutions: primer design, cDNA libraries, qPCR, and gene synthesis | $48M | 143 mo ago | 39 | 2009 | — | — | 278 patents High‑fidelity synthetic DNA/oligonucleotide assembly and production for genomics applications | — |
| 15 | TransMolecular Provider of tumor specific drug delivery technology | $48M | 208 mo ago | 7 | 1996 | — | — | 50 patents Chlorotoxin-based drug delivery systems targeting metastatic and angiogenic tumors | — |
| 16 | Stemgent Accelerating drug discovery and regenerative medicine through stem cell and tissue technologies | $43M | 166 mo ago | 51 | 2008 | — | — | 6 patents Derivation and preparation of pluripotent stem cells for regenerative medicine | — |
| 17 | WaveGuide Portable micro-nuclear magnetic resonance instruments for on-site testing and analysis | $41M | 13 mo ago | 6 | 2010 | Gregg Hershenson Co-Founder | — | 26 patents Low-field NMR instrumentation with advanced programmable-gain and switched-mode amplifiers | — |
| 18 | Lucy Therapeutics Developer of drugs for treating neurological disorders | $36M | 24 mo ago | 6 | 2017 | Amy Ripka CEO & Founder | — | — | — |
| 19 | Ensemble Therapeutics Engineering synthetic macrocycle drugs with a focus on Immune Checkpoint and Ubiquitin Proteasome Inhibitors | $30M | 223 mo ago | 35 | 2004 | — | — | — | — |
| 20 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | 48 | 2013 | Paul Roma Co-Founder | — | — | — |
| 21 | GnuBIO Provder of DNA sequencing platform based on microfluidic technology | $21M | 164 mo ago | 41 | 2009 | — | — | 92 patents Microfluidic droplet-based nucleic acid sequencing and fluorescence detection technologies | — |
| 22 | March Therapeutics Provider of multiple genome-based services | $20M | 45 mo ago | 7 | 2020 | Fahim Farzadfard Co-Founder | — | — | — |
| 23 | Amide Technologies Developer of automated peptide synthesis platform | $16M | 35 mo ago | 8 | 2017 | — | WordPressMySQLPHP+15 | — | — |
| 24 | DoubleRainbow Biosciences Developer of sustainable therapeutics and nutraceuticals using natural product manufacturing | $15M | 67 mo ago | 15 | 2017 | Tian Xu Co-Founder | — | — | — |
| 25 | Atantares Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies | $14M | 34 mo ago | 60 | 2020 | Xin Zhao Founder & CEO | — | 5 patents Point‑of‑care micro platelet function and viscoelastic blood coagulation diagnostics | — |
| 26 | Galenea Galenea | $14M | 165 mo ago | 51 | 2004 | Mark B. Benjamin President & CEO | — | 27 patents Neuropharmacology tools for synaptic vesicle assays, EEG biomarkers, and cognitive drug screening | — |
| 27 | Travera Developer of biomarker for personalized therapy in multiple myeloma | $13M | 59 mo ago | 9 | 2017 | Mark Stevens Co-founder and Interim CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | 44 patents Single-cell immunological diagnostics and cancer therapy selection using calibrated cellular measurement technologies | — |
| 28 | Hunterian Provider of gene-editing platform based on CRISPR delivery technology | $8M | 16 mo ago | 6 | 2004 | Vinod Ranga Founder & CEO | — | — | — |
| 29 | Strategic Science & Technologies Biotechnology firm pioneering topical drug delivery for female sexual arousal disorder | $5M | 149 mo ago | 2 | 1994 | — | — | 132 patents Pharmaceutical compounds and formulations for treating erectile dysfunction and related conditions. | — |
| 30 | Design Pharmaceuticals Developer of cell-based technologies for drug discovery and biosynthetic production | $5M | 52 mo ago | 23 | 2018 | Dirk Loeffert Founder & CEO | — | — | — |
| 31 | Parallel Bio Limited information available | $4M | 12 mo ago | 8 | 2020 | — | — | — | 3 job openings · 1 expansion |
| 32 | Korro Bio Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 26 mo ago | 77 77 → 75 (-3%) | 2018 | Josh Rosenthal Co-Founder | DrupalApple iCloud MailPHP+27 | — | — |
| 33 | TorpedoDx Developer of a proprietary cell sorting platform | $4M | 96 mo ago | — | 2017 | Daniel Haber Co-Founder | — | — | — |
| 34 | Firefly BioWorks Develops platform to allow multiplexed assays on standard laboratory instrumentation | $4M | 143 mo ago | 15 | 2009 | Davide M. Marini Co-Founder and Chief Executive Officer | — | 55 patents Multiplexed nucleic acid detection and substrate-mediated bioassay reactor technologies | — |
| 35 | Expansion Technologies Innovating brain research through advanced microscopy and simulation technologies | $4M | 16 mo ago | 2 | 2015 | Ed Boyden Co-Founder | — | 2 patents Pipe/tube expansion devices for mechanical deformation and fabrication processes. | — |
| 36 | Genometry Developer of technologies for low-cost gene expression profiling | $3M | 165 mo ago | 8 | 2012 | Arvind Subramanian Co-Founder | — | — | — |
| 37 | Etex Manufactures and commercializes a unique musculoskeletal platform of regenerative calcium phosphate… | $3M | 251 mo ago | 13,500 | 1989 | Stephen La Neve CEO & President | — | 124 patents Calcium phosphate bone grafts, osteoinductive materials, and delivery systems for bone repair | — |
| 38 | LifeCanvas Technologies Developer of tissue processing instruments and equipment | $3M | 36 mo ago | 22 | 2016 | — | WordPressMySQLPHP+30 | — | — |
| 39 | DeepBiome Therapeutics Developer of novel therapeutics addressing unmet needs in immune-related diseases | $3M | 80 mo ago | 7 | 2017 | Aleksandar D Kostic Founder | — | — | — |
| 40 | Advirna Developer of technology for ex-vivo and in-vivo oligonucleotide delivery | $2M | 68 mo ago | 7 | 2008 | Alexey Wolfson Chief Executive Officer And Chief Strategy Officer | WordPressMySQLPHP+23 | 3 patents Delivery technologies for small interfering RNA and therapeutic oligonucleotides | — |
| 41 | Nuture Genomics Healthcare company focused on genomics and newborn sequencing | $2M | 45 mo ago | 4 | 2021 | Natasha Bonhomme Co-Founder | — | — | — |
| 42 | Ligon Discovery Discovers drugs for oncology and coagulation disorders using SMM technology | $2M | 199 mo ago | 6 | 2009 | Angela Koehler Co-Founder | — | — | — |
| 43 | Pendar Technologies Provider of a spectroscopic analytical instrument system | $1M | 21 mo ago | 54 54 → 46 (-15%) | 2015 | Greg Rhodes Co-Founder | WordPressSentryZendesk+23 | 2 patents Quantum cascade laser array-based infrared spectroscopy systems | — |
| 44 | ScreenIn3D Revolutionizing drug discovery with predictive 3D human disease models | $1M | 12 mo ago | 4 | 2018 | Alex Sim CEO | — | — | — |
| 45 | IOTA Pharma Offering fragment-based drug discovery products and services | $906K | 113 mo ago | 3 | 2007 | — | — | — | — |
| 46 | Xenomics Developer of smart technology by using gene-editing technology | $600K | 71 mo ago | 8 | 2002 | Ryan Hubbard Co-Founder & CMO | — | 23 patents Liquid-biopsy nucleic acid detection and miRNA-based cell‑death diagnostics | — |
| 47 | Enable Life Sciences Provides portfolio of biotech services | $499K | 33 mo ago | — | 2013 | Rachit Ohri Founder & CEO | — | — | — |
| 48 | Genesis DNA Personalized software solutions bringing digital dreams to life with quality guaranteed | $250K | 128 mo ago | 3 | 2015 | Jefferson Clayton Co-Founder & CEO | — | — | — |
| 49 | XGenomes Developer of DNA sequencing technologies | $150K | 13 mo ago | 8 | 2013 | — | — | 38 patents Epigenetic DNA modification detection and random epigenomic sampling sequencing methods. | — |
Top 12 Life Sciences Platforms and Tools companies in Cambridge
#1
Acquired · Cambridge, Massachusetts · founded 2013 · 48 employees$28.9Mraised▾
Developer of transformational medicines for neurological disorders. The company combines advanced human cellular models, unique measurement engineering, artificial intelligence, and machine learning into a proprietary platform to discover new drugs for neurological disease. The company's lead candidate is UBE3A for Seizure and Neurodevelopment Disorders.
- Apr 2026Series B—
- Dec 2025Grant (prize money)$3M
- Jul 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.2M
#2
Series B · Cambridge, Maryland · founded 2010 · 6 employees$41.4Mraised▾
Portable micro-nuclear magnetic resonance instruments for on-site testing and analysis. This innovative technology offers rapid detection and quantification of substances, enabling critical medical, material, and diagnostic tests in various locations. The battery-powered, portable μNMR instrument facilitates quick and easy testing of diverse materials, including motor oil, olive oil, pharmaceuticals, and pathogens, without requiring specialized training. It caters to industries needing authenticity verification, purity measurement, wear and tear analysis, and pathogen detection. The technology can be tailored for specific organizational needs, offering solutions for oncology, pathogen detection, purity measurement, authenticity confirmation, and wear and tear assessment. This revolutionary technology provides on-site analysis, delivering faster results and cost savings.
- May 2025Conventional Debt$3M
- May 2022Series B$8.3M
- May 2019Series A$2.6M
- Nov 2018Series A$3.4M
#3
Series A · Cambridge, Massachusetts · founded 2020 · 8 employees$4.4Mraised▾
Limited information available
- Jun 2025Series A$21M
- Jan 2023Seed$4.3M
- 2021Seed$125K
#4
Series A · Cambridge, Massachusetts · founded 2004 · 6 employees$8.1Mraised▾
Provider of gene-editing platform based on CRISPR delivery technology. The company offers proprietary CRISPR delivery technology through a single adeno-associated virus (AAV) to cure genetic diseases by changing DNA mutations. They use a two-for-one genetic control element to overcome the problem of delivering CRISPR through AAV. Mutations in skeletal and cardiac muscle, lungs, brain, and other tissues can be diagnosed using CRISPR technology.
- Feb 2025Grant (prize money)$350K
- Jan 2025Grant (prize money)$320K
- Sep 2023Grant (prize money)$350K
- Aug 2022Grant (prize money)$320K
#5
Series B · Cambridge, Massachusetts · founded 2019 · 56 employees$211Mraised▾
Developer of RNA processing therapeutics to treat multiple diseases. The company has developed its proprietary REMaster technology platform to create therapeutics which is designed to reprogram RNA processing and treat disease. It is used to alter gene expression by correcting dysregulation/eliminating the gene message to cancers, central nervous system diseases, and rare genetic diseases.
- Dec 2023Series B$60M
- May 2022Series B$70M
- Dec 2020Series A$81M
#6
Acquired · Cambridge, Massachusetts · founded 2021 · 136 employees$300Mraised▾
Developer of RNA-based medicines to treat multiple diseases. The company combines novel RNA delivery platforms allowing for coding, editing, and gene insertion to develop new medicines.
- May 2023Series A$300M
#7
Series C · Cambridge, Massachusetts · founded 2017 · 203 employees$532Mraised▾
Tessera Therapeutics is a provider of new genome engineering technology for treating multiple diseases. It offers a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. It offers RNA gene writings that can change base pairs, make small insertions or deletions, and integrate entire genes into the genome.
- Apr 2022Series C$300M
- Jan 2021Series B$230M
- Dec 2017Series B$80M
#8
Series A · Cambridge, Massachusetts · founded 2015 · 2 employees$3.5Mraised▾
Innovating brain research through advanced microscopy and simulation technologies. The company pioneers computer simulations of the human brain, leveraging connectivity and molecular insights to revolutionize AI development, brain disease treatment, and our understanding of the human condition. They achieve this through novel tools, including expansion microscopy, optogenetics, and high-speed brain activity imaging. Expansion microscopy, a core invention, enables nanoprecise imaging of large-scale brain tissues with molecular information. This technology permeates brain tissue and physically expands it, allowing for detailed analysis. The company's work has potential social impact in healthcare and technology, pushing the boundaries of neuroscience and offering new avenues for research and discovery.
- Feb 2025Grant (prize money)$500K
- Sep 2022Grant (prize money)$500K
- Nov 2017Series A$1.5M
- Feb 2016Series A$2M
#9
Series B · Cambridge, Massachusetts · founded 2017 · 6 employees$36Mraised▾
LucyTherapeutics is developing drugs using mitochondrial technology for the treatment of neurological disorders such as Rett Syndrome. The drugs are developed for targets associated with disease pathogenesis and modulating mitochondrial function. The company has designed a dosing regimen for mimicking neuroprotective and cardioprotective properties.
- May 2024Grant (prize money)$2M
- May 2024Series B$10.5M
- Dec 2023Series B$3.4M
- Apr 2022Grant (prize money)$4.9M
#10
Series C · Cambridge, Massachusetts · founded 2016 · 85 employees$300.1Mraised▾
LifeMine Therapeutics is exploiting the ability of fungi to produce drugs and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms. The company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere.
- Mar 2022Series C$175M
- Jan 2021Series B$50M
- Mar 2019Series A$70.1M
- Sep 2016Series A$5M
#11
Seed · Cambridge, Massachusetts · founded 2018 · 4 employees$1Mraised▾
Revolutionizing drug discovery with predictive 3D human disease models. The company accelerates drug screening using cutting-edge technologies. They offer solutions for testing drug efficacy on predictive 3D human models of disease at scale, enabling faster and better data for small molecules, biologics, cell, and gene therapies. Their versatile platform supports testing multiple modalities, empowering drug developers to produce better drugs, faster, and with less cost. They provide large throughput, relevant models mimicking human disease environments, and customer-defined assays. The open platform is automation-friendly, supporting multiple readouts. They offer lab-on-a-chip solutions, disease models, and services to revolutionize clinical trials. This is a B2B tech company offering software solutions for the pharmaceutical industry.
- Jun 2025Seed$1M
#12
Public · Cambridge, Massachusetts · founded 2007 · 141 employees$97Mraised▾
Developer of assay kits for ultra-sensitive biomarker detection. The company’s ultra-sensitive detection solution, Simoa, for the disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.
- Mar 2022Grant (prize money)—
- Jun 2017Series D$8.5M
- Mar 2016Series D$46M
- Jul 2015Grant (prize money)$500K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Cambridge is moving
A read on the academic research around Bioinformatics in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 240 papers.
- University of Cambridge194
- Cancer Research UK Cambridge Center27
- Cambridge University Hospitals NHS Foundation Trust24
- Cambridge School15
- Wellcome/MRC Cambridge Stem Cell Institute8
- Gene2→13
- Genome2→12
- Transcriptome2→11
- DNA sequencing1→5
- Disease1→5
- Genome6
- Computational biology4
- Missense mutation3
- In silico3
- Biomarker3
- Disease2→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.